therapy
Among patients who started troglitazone therapy in 1998 (after the incorporation        of a boxed warning and increased monitoring requirements in the product       labelling), the estimated risk of liver-related death is approximately 1 in       100,000.
Among patients who started  @OBJECT$  @PREDICAT$  @SUBJECT$  in 1998 (after the incorporation        of a boxed warning and increased monitoring requirements in the product       labelling), the estimated risk of liver-related death is approximately 1 in       100,000.